Nabriva Therapeutics (NBRVF) 10-Q 7 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 15, 2017
Document and Entity Information
Entity Registrant Name	Nabriva Therapeutics plc
Entity Central Index Key	1,641,640
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shares Outstanding		26,838,260
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 20,089	$ 32,778
Short-term investments	33,084	51,106
Other receivables	8,699	5,561
Prepaid expenses	1,353	1,176
Total current assets	63,225	90,621
Property, plant and equipment, net	1,437	519
Intangible assets, net	211	270
Long-term receivables	408	420
Deferred tax assets	2,093	1,410
Total assets	67,374	93,240
Current liabilities:
Accounts payable	8,323	2,551
Accrued expense and other current liabilities	8,432	13,326
Total current liabilities	16,755	15,877
Non-current liabilities
Long-term debt	218
Other non-current liabilities	146	107
Total non-current liabilities	364	107
Total liabilities	17,119	15,984
Commitments and contingencies (Note 17)
Stockholders' Equity:
Common shares, no par value, 2,719,695 common shares issued and outstanding at December 31, 2016		2,939
Ordinary shares, par value $0.01, 1,000,000,000 ordinary shares authorized at June 30, 2017; 26,838,260 issued and outstanding at June 30, 2017	268
Preferred shares, par value $0.01, 100,000,000 shares authorized at June 30, 2017;none issued and outstanding at June 30, 2017
Additional paid in capital	283,960	279,149
Accumulated other comprehensive income (loss)	(16)	10
Accumulated deficit	(234,667)	(204,842)
Total Nabriva Therapeutics plc stockholders' equity	49,545	77,256
Non-controlling interest	710
Total stockholders' equity	50,255	77,256
Total liabilities and stockholders' equity	$ 67,374	$ 93,240

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Consolidated Balance Sheets
Common stock, no par value		$ 0
Common stock, issued shares		2,719,695
Common stock, outstanding shares		2,719,695
Ordinary stock, par value (in dollars per share)	$ 0.01
Ordinary stock, authorized shares	1,000,000,000
Ordinary stock, issued shares	26,838,260
Ordinary stock, outstanding shares	26,838,260
Preferred stock, par value (in dollars per share)	$ 0.01
Preferred stock, authorized shares	100,000,000
Preferred stock, issued shares	0
Preferred stock, outstanding shares	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Research premium and grant revenue	$ 1,051	$ 1,785	$ 2,729	$ 3,204
Operating expenses:
Research and development	(11,043)	(9,943)	(23,703)	(22,979)
General and administrative	(5,570)	(3,368)	(9,788)	(6,453)
Total operating expenses	(16,613)	(13,311)	(33,491)	(29,432)
Loss from operations	(15,562)	(11,526)	(30,762)	(26,228)
Other income (expense):
Other income (expense), net	(116)	(644)	90	354
Interest income	112	54	233	142
Interest expense	(3)		(4)
Loss before income taxes	(15,569)	(12,116)	(30,443)	(25,732)
Income tax benefit	967	12	618	29
Net loss	(14,602)	(12,104)	(29,825)	(25,703)
Other comprehensive income (loss), net of tax
Unrealized gains (losses) on available-for-sale financial assets	(10)	(8)	(26)	33
Other comprehensive income (loss), net of tax	(10)	(8)	(26)	33
Comprehensive loss	$ (14,612)	$ (12,112)	$ (29,851)	$ (25,670)
Loss per share
Basic and Diluted (in dollars per share)	$ (0.54)	$ (0.57)	$ (1.10)	$ (1.21)
Weighted average number of shares:
Basic and Diluted (in shares)	27,186,560	21,252,790	27,197,070	21,215,870

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss	$ (29,825)	$ (25,703)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other expense, net	(1,008)	(253)
Non-cash interest income	(63)	(65)
Depreciation and amortization expense	149	99
Stock-based compensation	2,876	1,405
Deferred income taxes	(683)	(31)
Other, net	105	1
Changes in operating assets and liabilities:
Changes in long-term receivables	12	(6)
Changes in other receivables and prepaid expenses	(3,315)	(3,039)
Changes in accounts payable	4,975	(1,097)
Changes in accrued expenses and other liabilities	(3,460)	3,550
Changes in other non-current liabilities	18	9
Net cash used in operating activities	(30,219)	(25,130)
Cash flows from investing activities
Purchases of plant and equipment and intangible assets	(236)	(307)
Purchases of available-for-sale securities		(14,000)
Proceeds from sales of property, plant and equipment	2
Proceeds from maturities of term deposits		15,000
Proceeds from sales of available-for-sale securities	18,000	15,000
Net cash provided by investing activities	17,766	15,693
Cash flows from financing activities
Proceeds from long-term debt	228
Proceeds from exercise of stock options	11	237
Equity offering costs	(1,483)
Net cash provided by (used in) financing activities	(1,244)	237
Effect of Exchange Rate on Cash and Cash Equivalents	1,008	253
Net decrease in cash and cash equivalents	(12,689)	(8,947)
Cash and cash equivalents at beginning of period	32,778	36,446
Cash and cash equivalents at end of period	$ 20,089	$ 27,499

Organization and Business Activ

Organization and Business Activities	6 Months Ended
	Jun. 30, 2017
Organization and Business Activities
Organization and Business Activities	1. Organization and Business Activities Nabriva Therapeutics plc (“Nabriva Ireland”), together with its 98.6% owned and consolidated Austrian subsidiary, Nabriva Therapeutics AG (“Nabriva AG”), and 100% owned and consolidated U.S. subsidiary Nabriva Therapeutics US, Inc. and 100% owned and consolidated Irish subsidiary Nabriva Therapeutics Ireland DAC, (collectively, “Nabriva”, the “Nabriva Group” or the “Company”) is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s headquarters are located at 25-28 North Wall Quay, Dublin, Ireland. On March 1, 2017, Nabriva Ireland was incorporated in Ireland under the name Hyacintho 2 plc, and was renamed to Nabriva Therapeutics plc on April 10, 2017, in order to effectuate the change of the jurisdiction of incorporation of the ultimate parent company of the Nabriva Group from Austria to Ireland. Nabriva Ireland replaced Nabriva AG as the ultimate parent company on June 23, 2017, following the conclusion of a tender offer (the “Exchange Offer”) in which holders of 98.5% of the outstanding share capital of Nabriva AG exchanged their holdings for ordinary shares, $0.01 nominal value per share, of Nabriva Ireland (the “Redomiciliation Transaction”). The ordinary shares of Nabriva Ireland were issued on a one-for-ten basis to the holders of the Nabriva AG common shares (“Nabriva AG common shares”) and on a one-for-one basis to the holders of the Nabriva AG American Depositary Shares (“Nabriva AG ADSs”) participating in the Exchange Offer. On June 26, 2017, the ordinary shares of Nabriva Ireland began trading on the NASDAQ Global Market under the symbol “NBRV,” the same symbol under which the American Depositary Shares of Nabriva AG were previously traded. This transaction was accounted for as a merger between entities under common control; accordingly, the historical financial statements of Nabriva AG for periods prior to this transaction are considered to be the historical financial statements of Nabriva Ireland. As of June 30, 2017, 98.6% of Nabriva AG share capital had been exchanged for ordinary shares of Nabriva Ireland. The Company currently expects to issue additional ordinary shares of Nabriva Ireland in exchange for the remaining 1.4% of Nabriva AG’s outstanding share capital in the third quarter of 2017. Nabriva AG was incorporated in Austria as a spin-off from Sandoz GmbH in October 2005 and commenced operations in February 2006. Nabriva Therapeutics US, Inc. was founded and began operations in the United States in August 2014. In February 2017, the Company purchased all shares issued in the capital of Hyacintho DAC, a designated activity company incorporated by a nominee company in December 2016 and renamed the company to Nabriva Therapeutics Ireland DAC on April 10, 2017. Throughout these Notes to the Unaudited Consolidated Financial Statements, unless the context requires otherwise, all references to “Nabriva,” “the Nabriva Group,” “the Company,” or similar terms on or prior to June 23, 2017 (the effective date of the Redomiciliation Transaction), refer to our predecessor, Nabriva AG, together with its subsidiaries. Certain share and per share amounts have been retrospectively adjusted to reflect the Exchange Offer and the Redomiciliation Transaction. Liquidity As of December 31, 2016, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 205-40, Presentation of Financial Statements - Going Concern (“ASC 205-40”), which requires management to assess the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. This standard requires management to 1) identify and disclose if there are initial conditions indicating substantial doubt about the Company’s ability to continue as a going concern within one year of the issuance date of the financial statements, 2) disclose the principal conditions that gave rise to substantial doubt, 3) disclose management’s evaluation of the significance of those conditions in relation to the Company’s ability to meet its obligations and 4) disclose management’s plans that are intended to mitigate the adverse conditions. In accordance with the accounting standard, when considering management’s plans to mitigate the conditions giving rise to substantial doubt, management can only consider those plans which are probable to be successfully implemented. As disclosed in its Annual Report on Form 10-K for the year ended December 31, 2016, the Company’s projected expenditures may deplete current cash, cash equivalents and investments in 2017 and 2018. As of June 30, 2017, management has further assessed this risk and, in accordance with the requirements of ASC 205-40, determined that there are conditions indicating that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the issuance date of these interim consolidated financial statements. Since its inception, the Company has incurred net losses and generated negative cash flows from its operations. To date, it has financed its operations through the sale of equity securities, including its initial public offering of Nabriva AG ADSs and private placements of its Nabriva AG common shares, convertible debt financings and research and development support from governmental grants and loans. As of June 30, 2017, the Company had cash and cash equivalents and short-term investments of $53.2 million. The Company anticipates that its expenses will increase substantially as it continues the development of and potentially seeks marketing approval for lefamulin and, possibly, other product candidates and continues its research activities. The Company’s expenses will increase if it suffers any delays in its Phase 3 clinical program for lefamulin for the treatment of community-acquired bacterial pneumonia (“ CABP”), including delays in enrollment of patients. If the Company obtains marketing approval for lefamulin or any other product candidate that it develops, it expects to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. Furthermore, the Company expects to incur additional costs associated with operating as a public company. The Company has developed plans to mitigate this risk, which primarily consist of raising additional capital through a combination of equity or debt financings, new collaborations, and reducing cash expenditures. The Company currently expects to seek funding in future periods. While the Company has raised capital in the past, the ability to raise capital in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in their assessment of the Company’s ability to meet its obligations for the next twelve months. If the Company is not able to secure adequate additional funding, the Company plans to make reductions in spending. This may include extending payment terms with suppliers, liquidating assets, and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend or eliminate one or more research and development programs or its commercialization efforts. The ability to reduce spending under this plan, at a level that mitigates the factors described above, is not considered probable, as defined in the accounting standards; as such, under the requirements of ASC 205-40, the full extent to which management may extend the Company’s funds through these actions may not be considered in management’s assessment of the Company’s ability to continue as a going concern for the next twelve months. As a result, in accordance with the requirements of ASC 205-40, management has concluded that it is required to disclose that substantial doubt exists about the Company’s ability to continue as a going concern for one year from the date these financial statements are issued. While management has plans in place to mitigate these actions, they are not considered probable, as defined in the accounting standards, and a failure to raise the additional funding or to effectively implement cost reductions could harm the Company’s business, results of operations and future prospects. The interim consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Based on current projections, the company anticipates availability of top-line clinical data from LEAP 1, its first Phase 3 clinical trial of lefamulin for CABP, in September of 2017. In addition, the Company expects to complete patient enrollment for LEAP 2, its second Phase 3 clinical trial of lefamulin for CABP, in the fourth quarter of 2017 and anticipates availability of top-line data for LEAP 2 in the first quarter of 2018.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Preparation The unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and U.S. Securities and Exchange Commission (“SEC”) regulations for quarterly reporting. The accompanying consolidated financial information as of June 30, 2017 and for the three and six months ended June 30, 2016 and 2017 is unaudited. The December 31, 2016 condensed balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by US GAAP. The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2017 and for the three and six months ended June 30, 2016 and 2017. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2016 and 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017, any other interim periods or any future year or period. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K, as filed with the SEC on March 24, 2017. The Company’s significant accounting policies are described in Note 2 of the notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies. Recent Accounting Pronouncements At the time of authorization of these consolidated financial statements for publication, a number of revisions, amendments and interpretations had already been published by the Financial Accounting Standards Board (FASB). None of these are expected to have a significant effect on the consolidated financial statements of the Company, except the following set out below: · In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or US GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. ASU 2014-09 will have no impact on the Company until it begins to generate product revenue. · In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the balance sheet classification of deferred taxes and requires that all deferred taxes be presented as noncurrent. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures. · In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-01 will have on its financial statements and related disclosures. · In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures. · In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting , which provides for simplification of certain aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 was effective in the first quarter of 2017. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures.

Research Premium and Grant Reve

Research Premium and Grant Revenue	6 Months Ended
	Jun. 30, 2017
Research Premium and Grant Revenue
Research Premium and Grant Revenue	3. Research Premium and Grant Revenue Research premium and grant revenue consists of the following items: Three Months Ended Six Months Ended (in thousands) 2016 2017 2016 2017 Research premium $ $ $ $ Government grants — — Grants from WWFF Total $ $ $ $ Research premium and grant revenue comprises (1) the research premium from the Austrian government, (2) grants received from the Austrian Research Promotion Agency ( Österreichische Forschungsförderungsgesellschaft, or FFG ) and the Vienna Business Promotion Fund ( Wiener Wirtschaftsförderungsfonds, or WWFF ) and (3) the benefit of government loans at below-market interest rates. The research premium the Company receives from the Austrian government is calculated at a specified percent of specified research and development cost base. The Company recognizes the research premium as long as it has incurred research and development expenses. The WWFF grant is paid out through the landlord in the form of a monthly reduction in lease payments and is recognized over the period from grant date in March 2010 until end of the lease termination waiver term in December 2017. All grants are non-refundable as long as the conditions of the grant are met. The Company is and has been in full compliance with the conditions of the grants and all related regulations.

Research and Development Expens

Research and Development Expenses	6 Months Ended
	Jun. 30, 2017
Research and Development Expenses
Research and Development Expenses	4. Research and Development Expenses Research and development expenses include the following items: Three Months Ended Six Months Ended (in thousands) 2016 2017 2016 2017 Research materials and purchased services $ $ $ $ Staff costs Other research and development expenses Depreciation and amortization Total $ $ $ $ Research materials and purchased services include all expenses for materials and services in respect of research activities. For the three and six months ended June 30, 2017, other research and development expenses consisted of $0.4 million and $0.7 million, respectively, in infrastructure expenses, $0.7 million and $1.0 million, respectively, in advisory and external consultancy expenses and $0.2 million and $0.3 million, respectively, in intellectual property and trademark related expenses and travel expenses. For the three and six months ended June 30, 2016, other research and development expenses consisted of $0.3 million and $0.6 million, respectively, in infrastructure expenses, $0.5 million and $0.8 million, respectively, in advisory and external consultancy expenses, $0.1 million and $0.2 million, respectively, in intellectual property and trademark related expenses, $0.1 million and $0.2 million, respectively, in travel expenses and $0.1 million and $0.1 million, respectively, in other expenses.

General and Administrative Expe

General and Administrative Expenses	6 Months Ended
	Jun. 30, 2017
General and Administrative Expenses
General and Administrative Expenses	5. General and Administrative Expenses General and administrative expenses include the following items: Three Months Ended Six Months Ended (in thousands) 2016 2017 2016 2017 Other general and administrative expenses $ $ $ $ Staff costs Depreciation and amortization Total $ $ $ $ For the three and six months ended June 30, 2017, other general and administrative expenses included the following: $1.0 million and $1.7 million, respectively, of advisory and external consultancy expenses, $0.2 million and $0.4 million, respectively, of tax consulting, payroll accounting, accounting and auditing expenses, $0.3 million and $0.7 million, respectively, in infrastructure expenses, $1.3 million and $2.3 million, respectively, of legal expenses, $0.1 million and $0.2 million, respectively, of travel expenses, $0.1 million and $0.2 million, respectively, in supervisory board fees and expenses and $0.3 million and $0.6 million, respectively, of other expenses. For the three and six months ended June 30, 2016, other general and administrative expenses included the following: $0.6 million and $1.0 million, respectively, of advisory and external consultancy expenses, $0.1 million and $0.2 million, respectively, of tax consulting, payroll accounting, accounting and auditing expenses, $0.3 million and $0.6 million, respectively, in infrastructure expenses, $0.3 million and $0.6 million, respectively, of legal expenses, $0.1 million and $0.2 million, respectively, of travel expenses, $0.2 million and $0.3 million, respectively, in supervisory board fees and expenses and $0.3 million and $0.6 million, respectively, of other expenses.

Post-employment benefit obligat

Post-employment benefit obligations	6 Months Ended
	Jun. 30, 2017
Post-employment benefit obligations
Post-employment benefit obligations	6. Post-employment benefit obligations As required under Austrian labor law, the Company makes contributions to a state plan classified as defined contribution plan ( Mitarbeitervorsorgekasse ) for its employees in Austria. Monthly contributions to the plan are 1.53% of salary with respect to each employee and are recognized as expense in the period incurred. In the three months ended June 30, 2017 and 2016, contribution costs were $16,000 and $19,000, respectively. In the six months ended June 30, 2017 and 2016, contribution costs were $27,000 and $30,000, respectively. For employees of Nabriva Therapeutics US, Inc., the Company makes contributions to a defined contribution plan as defined in subsection 401(k) of the Internal Revenue Code. The Company matches 100% of the first 3% of the employee’s voluntary contribution to the plan and 50% of the next 2% contributed by the employee. Contributions are recognized as expense in the period incurred. In the three months ended June 30, 2017 and 2016 contribution expenses were approximately $51,000 and $32,000, respectively. In the six months ended June 30, 2017 and 2016 contribution expenses were approximately $97,000 and $73,000, respectively.

Income tax (expense) benefit

Income tax (expense) benefit	6 Months Ended
	Jun. 30, 2017
Income tax (expense) benefit
Income tax (expense) benefit	7. Income tax (expense) benefit In accordance with the FASB Accounting Standard Codification (ASC) Topic No. 270 “Interim Reporting” and ASC Topic No. 740 “Income Taxes” (Topic No. 740) at the end of each interim period, the Company is required to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three months ended June 30, 2017, the Company recorded a tax benefit of $967,000 and for the three months ended June 30, 2016, the Company recorded a tax benefit of $12,000. For the six months ended June 30, 2017, the Company recorded a tax benefit of $618,000 and for the six months ended June 30, 2016, the Company recorded a tax benefit of $29,000. As of June 30, 2017 and December 31, 2016, the Company had a non-current deferred tax assets of $2.1 million and $1.4 million, respectively. The deferred tax asset relates to tax attributes of the Company’s U.S. subsidiary, Nabriva Therapeutics US, Inc. The Company maintains a valuation allowance against certain deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits. On the basis of this evaluation, as of June 30, 2017 and December 31, 2016, the Company has recorded a valuation allowance of $58,973 and $54,114, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as the Company’s projections for growth.

Earnings (Loss) per Share

Earnings (Loss) per Share	6 Months Ended
	Jun. 30, 2017
Earnings (Loss) per Share
Earnings (Loss) per Share	8. Earnings (Loss) per Share Basic earnings/losses per share Basic earnings/losses per share is calculated by dividing the net earnings/loss attributable to shareholders by the weighted average number of shares outstanding during the year. Three Months Ended Six Months Ended (in thousands) 2016 2017 2016 2017 Net loss for the period $ ) $ ) $ ) $ ) Weighted average number of shares outstanding Excluded treasury shares on June 30 — — Basic loss per share $ ) $ ) $ ) $ ) Diluted earnings/losses per share Diluted earnings/losses per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares. The effect of 2,930,110 and 1,858,600 potentially dilutive share options has been excluded from the diluted loss per share calculations as of June 30, 2017 and 2016, respectively because it would result in a decrease in the loss per share for the period and is therefore not to be treated as dilutive.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2017
Fair Value Measurement
Fair Value Measurement	9. Fair Value Measurement US GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: · Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. · Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (as exchange rates). · Level 3: Valuation techniques that include inputs for the asset or liability that are not based on observable market data (those are unobservable inputs) and significant to the overall fair value measurement. The following table presents the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy: (in thousands) Level 1 Level 2 Level 3 Total As of December 31, 2016 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term deposits — — Total Assets $ $ $ — $ (in thousands) Level 1 Level 2 Level 3 Total As of June 30, 2017 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term deposits — — Total Assets $ $ $ — $ As of June 30, 2017 and December 31, 2016, the Company held short-term investments (see Note 11) classified as both Level 1 and Level 2, and the Company did not hold any Level 3 financial instruments measured at fair value. There were no transfers between Level 1 and 2 in the six months ended June 30, 2017 or the year ended December 31, 2016. There were no changes in valuation techniques during the six months ended June 30, 2017. As of June 30, 2017 and December 31, 2016, the Company did not hold any financial instruments as liabilities that were held at fair value. Other receivables and accounts payable are carried at their historical cost which approximates fair value due to their short term nature.

Long-term and current receivabl

Long-term and current receivables	6 Months Ended
	Jun. 30, 2017
Long-term and current receivables
Long-term and current receivables	10. Long-term and current receivables (in thousands) As of As of Deposits $ $ Total long-term receivables $ $ Research premium VAT and other taxes Receivables from grant revenue Other receivables Total current receivables $ $ Total $ $ Long-term receivables relate to rent deposits made on the office building in Vienna, Austria and King of Prussia, Pennsylvania, United States. Current receivables are all due within one year. No receivables are past due or impaired.

Short-term investments

Short-term investments	6 Months Ended
	Jun. 30, 2017
Short-term investments
Short-term investments	11. Short-term investments The Company’s short-term investments were as follows: As of December 31, 2016 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of June 30, 2017 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of June 30, 2017 and December 31, 2016, the Company’s short-term investments were classified as available-for-sale and comprised a (i) money market fund that invests all of its assets, excluding cash and deposits, in short term U.S. dollar-denominated debt securities, and (ii) a U.S. treasury note.

Share-Based Payments

Share-Based Payments	6 Months Ended
	Jun. 30, 2017
Share-Based Payments
Share-Based Payments	12. Share-Based Payments Stock Option Plan 2007 On September 12, 2007 the Company’s management and supervisory boards resolved to implement a stock option plan (“SOP 2007”) for all employees (including members of the management board) with open-ended contracts of employment with the Company and for selected members of the supervisory board of the Company and further participants. The stock option plan became effective on September 28, 2007 and the shareholders of the Company resolved to amend the SOP 2007 on September 17, 2009, May 7, 2010 and June 30, 2015. The total number of options that were eligible to be granted and vested in the beneficiaries under the SOP 2007 did not exceed 29,889 Nabriva AG common shares (the overall number of options under the SOP 2007). In connection with the Redomiciliation Transaction, the SOP 2007 was amended to take account of certain requirements under Irish law and assumed by Nabriva Ireland, with each option to acquire one Nabriva AG common share becoming an option to acquire ten ordinary shares of Nabriva Ireland on the same terms and conditions. The options grant the beneficiaries the right to acquire shares in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. On the last day of the last calendar month of the second year of the vesting period, a further 25% of the options are vested. During the third and fourth years of the vesting period, the remaining 50% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Notwithstanding any of the above, the exercise of vested options was only permissible in case of a liquidation event (e.g. sale of 50% or more of the shares or assets of the Company or merger of the Company) or a qualified public offering. Since the closing of the initial public offering of the Company on September 23, 2015 the beneficiaries are entitled to exercise their vested options until the end of the exercise period on September 27, 2017. The beneficiaries are not entitled to transfer vested options except to individuals by way of inheritance or bequest. Options do not entitle beneficiaries to exercise any shareholder rights. Beneficiaries may exercise shareholder rights if and to the extent such beneficiary otherwise holds shares. Movements in the number of share options outstanding and their related weighted average exercise prices concerning the SOP 2007 are as follows: 2017 Stock Option Plan 2007 Options Weighted Aggregate Outstanding as of January 1, 2017 Granted — — Exercised ) Forfeited — — Outstanding as of June 30, 2017 $ Vested and exercisable as of June 30, 2017 $ The total intrinsic value of options exercised during the six months ended June 30, 2017 was $479,000. The weighted average remaining contractual life of all options granted under the SOP 2007 is 0.1 years. Stock-based compensation expense under the Stock Option Plan 2007 was $15,000 and $30,000 for the three and six months ended June 30, 2017, respectively. We did not accrue any income tax benefit under the Stock Option Plan 2007 for the three and six months ended June 30, 2017. The weighted average share price at the date of exercise of options exercised during the six months ended June 30, 2017 was $9.79. Stock Option Plan 2015 On April 2, 2015, the Company’s shareholders, management board and supervisory board adopted the Stock Option Plan 2015 and the shareholders approved an amended and restated version of the Stock Option Plan 2015 on June 30, 2015. An amendment to the amended and restated Stock Option Plan 2015 was approved by the shareholders on July 22, 2015. The Stock Option Plan 2015 became effective on July 3, 2015 upon the registration with the commercial register in Austria of the conditional capital increase approved by the shareholders on June 30, 2015. The Stock Option Plan 2015 initially provided for the grant of options for up to 95,000 Nabriva AG common shares to the Company’s employees, including members of the management board, and to members of the supervisory board. Following the closing of the initial public offering of the Company, the overall number of options increased to 177,499 Nabriva AG common shares. Following approval by the Company’s shareholders at its 2016 annual general meeting, the number of shares available for issuance under the Stock Option Plan 2015 was increased to 346,235 Nabriva AG common shares. In connection with the Redomiciliation Transaction, the Stock Option Plan 2015 was amended to take account of certain requirements under Irish law and assumed by Nabriva Ireland, with each option to acquire one Nabriva AG common share becoming an option to acquire ten ordinary shares of Nabriva Ireland on the same terms and conditions. Each vested option grants the beneficiary the right to acquire one share in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. During the second, third and fourth years of the vesting period, the remaining 75% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Options granted under the Stock Option Plan 2015 have a term of no more than ten years from the beneficiary’s date of participation. The beneficiaries are not entitled to transfer vested options except to individuals by way of inheritance or bequest. Options do not entitle beneficiaries to exercise any shareholder rights. Beneficiaries may only exercise shareholder rights if and to the extent such beneficiary otherwise holds shares. Movements in the number of share options outstanding and their related weighted average exercise prices under the Stock Option Plan 2015 are as follows: 2017 Stock Option Plan 2015 Options Weighted Aggregate Outstanding as of January 1, 2017 Granted Exercised — — Forfeited ) Outstanding as of June 30, 2017 $ Vested and exercisable as of June 30, 2017 $ Stock-based compensation expense under the Stock Option Plan 2015 was approximately $1.1 million and $2.9 million for the three and six months ended June 30, 2017, respectively. The weighted average fair value of the options granted during the six months ended June 30, 2017 was $4.86, per share. The 1,150,600 options granted in the six months ended June 30, 2017, were valued based on a Black Scholes option pricing model using the following assumptions. The significant inputs into the model were as follows: Input parameters Range of expected volatility 55.6% - 58.1% Expected term of options (in years) 6.1 Range of risk-free interest rate 1.9% - 2.1% Dividend yield — The expected price volatility is based on historical trading volatility for the publicly traded peer companies under consideration of the remaining life of the options. The weighted average remaining contractual life of the options as of June 30, 2017 is 8.8 years. As of June 30, 2017, there was $11.1 million of total unrecognized compensation expense, related to unvested options granted under the Stock Option Plan 2015, which will be recognized over the weighted-average remaining vesting period of 1.5 years.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2017
Accrued Expenses and Other Liabilities
Accrued Expenses and Other Liabilities	13. Accrued Expenses and Other Liabilities Other non-current liabilities include an obligation to pay jubilee benefits arising under the collective bargaining agreement for the chemical industry, by which employees in Austria are entitled to receive jubilee payments after being employed for a certain number of years. For this obligation a provision of $125,000 and $107,000 has been made as of June 30, 2017 and December 31, 2016, respectively. The Company’s net obligation in respect of the jubilee payments is calculated annually by an independent actuary in accordance with ASC 710-10-25 using the projected unit credit method. The principle actuarial assumptions used were as follows: discount rate of 1.3% and retirement at the age of 61.5-65 for men and 56.5-65 for women, future annual salary increases of 3%. Accrued expenses and other current liabilities include the following: (in thousands) As of As of Research and development related costs $ $ Payroll and related costs Accounting, tax and audit services Other Total other current liabilities $ $

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies
Commitments and Contingencies	14. Commitments and Contingencies Commitments Lease Agreements In March 2007, the Company entered into a lease agreement for an unlimited period starting in December 2007 with CONTRA Liegenschaftsverwaltung GMBH for the use of business and research premises at Leberstrasse 20, 1110 Vienna. Within the first 10 years the contract can only be terminated under certain conditions. The monthly rental fee for the premises and laboratory furniture was $84,000 and $85,000, as of June 30, 2017 and December 31, 2016, respectively, and includes all operating costs. Additional monthly costs for facility management and security services amounted to $9,000 and $9,000 as of June 30, 2017 and December 31, 2016, respectively. In July 2015, the Company entered into a lease agreement with CardConnect, LLC, for the use of office premises at 1000 Continental Drive, Suite 600, King of Prussia, PA 19406, USA with the lease term continuing until December 2023. The monthly base rental fee was approximately $40,000 and $40,000 as of June 30, 2017 and December 31, 2016, respectively. The obligations under the lease agreements are payable as follows: (in thousands) As of As of No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years Total $ $ Other contractual commitments In addition to the agreements described above, the Company has entered into a number of other agreements also entailing financial commitments for the future and relating mainly to services provided by third parties in connection with the conduct of clinical trials and other research and development activities. Some of these commitments are also subject to early termination clauses exercisable at the option of the Company. The remaining payments to be made under these agreements, if all milestones and other conditions are met, are estimated to be as follows: (in thousands) As of As of No later than 1 year $ $ Later than 1 year and no later than 5 years Total $ $ Contingencies The Company has no contingent liabilities in respect of legal claims arising in the ordinary course of business.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events
Subsequent Events	15. Subsequent Events The Company evaluated all events or transactions that occurred subsequent to June 30, 2017 through the date the unaudited consolidated financial statements were issued, and have not identified any such events material to an understanding of the unaudited consolidated financial statements.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Summary of Significant Accounting Policies
Basis of Preparation	Basis of Preparation The unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and U.S. Securities and Exchange Commission (“SEC”) regulations for quarterly reporting. The accompanying consolidated financial information as of June 30, 2017 and for the three and six months ended June 30, 2016 and 2017 is unaudited. The December 31, 2016 condensed balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by US GAAP. The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2017 and for the three and six months ended June 30, 2016 and 2017. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2016 and 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017, any other interim periods or any future year or period. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K, as filed with the SEC on March 24, 2017. The Company’s significant accounting policies are described in Note 2 of the notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies.
Recent Accounting Pronouncements	Recent Accounting Pronouncements At the time of authorization of these consolidated financial statements for publication, a number of revisions, amendments and interpretations had already been published by the Financial Accounting Standards Board (FASB). None of these are expected to have a significant effect on the consolidated financial statements of the Company, except the following set out below: · In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or US GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. ASU 2014-09 will have no impact on the Company until it begins to generate product revenue. · In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the balance sheet classification of deferred taxes and requires that all deferred taxes be presented as noncurrent. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures. · In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-01 will have on its financial statements and related disclosures. · In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures. · In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting , which provides for simplification of certain aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 was effective in the first quarter of 2017. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures.

Research Premium and Grant Re22

Research Premium and Grant Revenue (Tables)	6 Months Ended
	Jun. 30, 2017
Research Premium and Grant Revenue
Schedule of research premium and grant revenue	Three Months Ended Six Months Ended (in thousands) 2016 2017 2016 2017 Research premium $ $ $ $ Government grants — — Grants from WWFF Total $ $ $ $

Research and Development Expe23

Research and Development Expenses (Tables)	6 Months Ended
	Jun. 30, 2017
Research and Development Expenses
Schedule of research and development expenses	Three Months Ended Six Months Ended (in thousands) 2016 2017 2016 2017 Research materials and purchased services $ $ $ $ Staff costs Other research and development expenses Depreciation and amortization Total $ $ $ $

General and Administrative Ex24

General and Administrative Expenses (Tables)	6 Months Ended
	Jun. 30, 2017
General and Administrative Expenses
Schedule of General and Administrative expenses	Three Months Ended Six Months Ended (in thousands) 2016 2017 2016 2017 Other general and administrative expenses $ $ $ $ Staff costs Depreciation and amortization Total $ $ $ $

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings (Loss) per Share
Schedule of basic earnings/losses per share	Three Months Ended Six Months Ended (in thousands) 2016 2017 2016 2017 Net loss for the period $ ) $ ) $ ) $ ) Weighted average number of shares outstanding Excluded treasury shares on June 30 — — Basic loss per share $ ) $ ) $ ) $ )

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Measurement
Schedule of the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy	(in thousands) Level 1 Level 2 Level 3 Total As of December 31, 2016 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term deposits — — Total Assets $ $ $ — $ (in thousands) Level 1 Level 2 Level 3 Total As of June 30, 2017 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term deposits — — Total Assets $ $ $ — $

Long-term and current receiva27

Long-term and current receivables (Tables)	6 Months Ended
	Jun. 30, 2017
Long-term and current receivables
Schedule of long-term and current receivables	(in thousands) As of As of Deposits $ $ Total long-term receivables $ $ Research premium VAT and other taxes Receivables from grant revenue Other receivables Total current receivables $ $ Total $ $

Short-term investments (Tables)

Short-term investments (Tables)	6 Months Ended
	Jun. 30, 2017
Short-term investments
Schedule of short-term investments	As of December 31, 2016 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of June 30, 2017 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $

Share-Based Payments (Tables)

Share-Based Payments (Tables)	6 Months Ended
	Jun. 30, 2017
Stock Option Plan 2007
Share-Based Payments
Schedule of movements of share options outstanding and their related weighted average exercise prices	2017 Stock Option Plan 2007 Options Weighted Aggregate Outstanding as of January 1, 2017 Granted — — Exercised ) Forfeited — — Outstanding as of June 30, 2017 $ Vested and exercisable as of June 30, 2017 $
Stock Option Plan 2015
Share-Based Payments
Schedule of movements of share options outstanding and their related weighted average exercise prices	2017 Stock Option Plan 2015 Options Weighted Aggregate Outstanding as of January 1, 2017 Granted Exercised — — Forfeited ) Outstanding as of June 30, 2017 $ Vested and exercisable as of June 30, 2017 $
Schedule of inputs to the option pricing method	Input parameters Range of expected volatility 55.6% - 58.1% Expected term of options (in years) 6.1 Range of risk-free interest rate 1.9% - 2.1% Dividend yield —

Accrued Expenses and Other Li30

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Accrued Expenses and Other Liabilities
Schedule of accrued expenses and other current liabilities	(in thousands) As of As of Research and development related costs $ $ Payroll and related costs Accounting, tax and audit services Other Total other current liabilities $ $

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies
Schedule of obligations payable under the lease agreements	(in thousands) As of As of No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years Total $ $
Schedule of remaining payments to be made under other contractual agreements	(in thousands) As of As of No later than 1 year $ $ Later than 1 year and no later than 5 years Total $ $

Organization and Business Act32

Organization and Business Activities - General (Details)	Jun. 30, 2017
Nabriva Therapeutics AG
Percentage ownership by reporting entity	98.60%
Nabriva Therapeutics US, Inc.
Percentage ownership by reporting entity	100.00%
Nabriva Therapeutics Ireland DAC
Percentage ownership by reporting entity	100.00%

Organization and Business Act33

Organization and Business Activities - Redomiciliation Transaction (Details) - $ / shares	Sep. 30, 2017	Jun. 30, 2017	Jun. 23, 2017	Mar. 01, 2017
Stock Exchanges
Nominal value of ordinary stock (in dollars per share)		$ 0.01	$ 0.01
Redomiciliation Transaction | Nabriva Therapeutics AG
Stock Exchanges
Percent of outstanding share capital exchanged		98.60%	98.50%
Redomiciliation Transaction | Nabriva Therapeutics AG | Forecasted
Stock Exchanges
Ratio of exchange of ordinary shares	1.40%
Redomiciliation Transaction | Common Stock | Nabriva Therapeutics AG
Stock Exchanges
Ratio of exchange of ordinary shares			10.00%
Redomiciliation Transaction | ADS | Nabriva Therapeutics AG
Stock Exchanges
Ratio of exchange of ordinary shares				100.00%

Organization and Business Act34

Organization and Business Activities - Liquidity (Details) $ in Millions	Jun. 30, 2017USD ($)
Cash and cash equivalents and short term investments
Cash and cash equivalents and short term investments	$ 53.2

Research Premium and Grant Re35

Research Premium and Grant Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research Premium and Grant Revenue
Research premium	$ 871	$ 1,759	$ 2,376	$ 3,151
Government grants	154		301
Grants from WWFF	26	26	52	53
Total	$ 1,051	$ 1,785	$ 2,729	$ 3,204

Research and Development Expe36

Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research and development expenses
Depreciation and amortization			$ 149	$ 99
Total	$ 11,043	$ 9,943	23,703	22,979
Research and development expenses
Research and development expenses
Research materials and purchased services	6,551	6,918	16,159	17,102
Staff costs	3,159	1,952	5,479	3,937
Other research and development expenses	1,303	1,041	2,002	1,879
Depreciation and amortization	30	32	63	61
Total	11,043	9,943	23,703	22,979
Other research and development expenses
Other research and development expenses
Infrastructure expenses	400	300	700	600
Advisory and external consultancy expenses	700	500	1,000	800
Intellectual property and trademark related expenses	$ 200	100	$ 300	200
Travel expenses		100		200
other expenses		$ 100		$ 100

General and Administrative Ex37

General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
General and Administrative Expenses
Depreciation and amortization			$ 149	$ 99
Total	$ 5,570	$ 3,368	9,788	6,453
General and administrative expenses
General and Administrative Expenses
Other general and administrative expenses	3,310	1,879	6,107	3,528
Staff costs	2,217	1,467	3,595	2,887
Depreciation and amortization	43	22	86	38
Total	5,570	3,368	9,788	6,453
Other general and administrative expenses
Other general and administrative expenses
Advisory and external consultancy expenses	1,000	600	1,700	1,000
Tax consulting, payroll accounting, accounting and auditing expenses	200	100	400	200
Infrastructure expenses	300	300	700	600
Legal expenses	1,300	300	2,300	600
Travel expenses	100	100	200	200
Supervisory board fees and expenses	100	200	200	300
Other expenses	$ 300	$ 300	$ 600	$ 600

Post-employment benefit oblig38

Post-employment benefit obligations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Austria
Monthly contribution (as a percent)			1.53%	1.53%
Contribution costs	$ 16,000	$ 19,000	$ 27,000	$ 30,000
U.S.
Contribution costs	$ 51,000,000	$ 32,000,000	$ 97,000,000	$ 73,000,000
Percent of match, first level			100.00%	100.00%
Employee voluntary contribution, first level			3.00%	3.00%
Percent match, second level			50.00%	50.00%
Employee voluntary contribution, second level			2.00%	2.00%

Income tax (expense) benefit (D

Income tax (expense) benefit (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income tax (expense) benefit
Income tax expense (benefit)	$ (967,000)	$ (12,000)	$ (618,000)	$ (29,000)
Non-current deferred tax asset	2,093,000		2,093,000		$ 1,410,000
Valuation allowance - current and noncurrent	$ 58,973		$ 58,973		$ 54,114

Earnings (Loss) per Share (Deta

Earnings (Loss) per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Basic earnings/losses per share
Net loss	$ (14,602)	$ (12,104)	$ (29,825)	$ (25,703)
Weighted average number of shares outstanding	27,186,560	21,252,790	27,197,070	21,215,870
Excluded treasury shares on June 30		10,390		10,390
Basic loss per share	$ (0.54)	$ (0.57)	$ (1.10)	$ (1.21)
Antidilutive share options
Number of outstanding share options excluded from computation of diluted earnings per share			2,930,110	1,858,600

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Short-term investments:
Transfer of assets from Level 1 to 2	$ 0	$ 0
Transfer of assets from Level 2 to 1	0	0
Recurring
Short-term investments:
Available-for-sale investments	33,054	51,076
Term Deposits	30	30
Total Assets	33,084	51,106
Level 1 | Recurring
Short-term investments:
Available-for-sale investments	15,035	15,017
Term Deposits	30	30
Total Assets	15,065	15,047
Level 2 | Recurring
Short-term investments:
Available-for-sale investments	18,019	36,059
Total Assets	$ 18,019	$ 36,059

Long-term and current receiva42

Long-term and current receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Long-term receivables
Deposits	$ 408	$ 420
Total long-term receivables	408	420
Current receivables
Research premium	8,265	5,346
VAT and other taxes	138	46
Receivables from grant revenue	156	144
Other receivables	140	25
Total current receivables	8,699	5,561
Total long-term and current receivables	9,107	5,981
Receivables additional disclosures
Past due receivables	0	0
Impaired receivables	$ 0	$ 0

Short-term investments (Details

Short-term investments (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Short-term investments
Amortized Cost	$ 33,110	$ 51,124
Unrealized Losses	(26)	(18)
Fair Value	33,084	51,106
Available-for-sale investments
Short-term investments
Amortized Cost	33,080	51,094
Unrealized Losses	(26)	(18)
Fair Value	33,054	51,076
Term deposits
Short-term investments
Amortized Cost	30	30
Fair Value	$ 30	$ 30

Share-Based Payments - Stock Op

Share-Based Payments - Stock Option Plan 2007 (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 23, 2017	Sep. 12, 2007
Stock Option Plan 2007
Options
Outstanding at beginning of year (in shares)		109,960
Exercised (in shares)		(52,820)
Outstanding at end of year (in shares)	57,140	57,140
Vested and exercisable at end of year (in shares)	56,640	56,640
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)		$ 0.73
Exercised (in dollars per share)		0.73
Outstanding balance at end of year (in dollars per share)	$ 0.73	0.73
Vested and exercisable balance at end of year (in dollars per share)	$ 0.73	$ 0.73
Aggregate intrinsic value
Outstanding at end of year (in dollars)	$ 577,000	$ 577,000
Vested and exercisable at end of year (in dollars)	552,000	552,000
Total intrinsic value of options exercised		$ 479,000
Other disclosures
Weighted-average remaining contractual life		1 month 6 days
Share-based compensation expense (in dollars)	$ 15,000	$ 30,000
Weighted average of share price at the date of exercise of options (in dollars per share)	$ 9.79	$ 9.79
Stock Option Plan 2007 | Options
Share-Based Payments
Vesting period		4 years
Minimum percentage of shares or asset sale to permit exercise		50.00%
Stock Option Plan 2007 | Options | First year
Share-Based Payments
Vesting period		1 year
Percentage that vests during the period		25.00%
Stock Option Plan 2007 | Options | Second year
Share-Based Payments
Vesting period		2 years
Percentage that vests during the period		25.00%
Stock Option Plan 2007 | Options | Third and fourth years
Share-Based Payments
Vesting period		4 years
Percentage that vests during the period		50.00%
Monthly vesting percentage		2.083%
Nabriva Therapeutics AG | Common Stock | Stock Option Plan 2007
Share-Based Payments
Number of awards that can be granted				29,889
Redomiciliation Transaction | Nabriva Therapeutics AG | Common Stock
Share-Based Payments
Ratio of exchange of ordinary shares			10.00%
Redomiciliation Transaction | Nabriva Therapeutics AG | Common Stock | Stock Option Plan 2007
Share-Based Payments
Ratio of exchange of ordinary shares			10.00%

Share-Based Payments - Stock 45

Share-Based Payments - Stock Option Plan 2015 (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 23, 2017	Aug. 25, 2016	Sep. 23, 2015	Apr. 02, 2015
Stock Option Plan 2015
Share-Based Payments
Exercise period	10 years
Options
Outstanding at beginning of year (in shares)	1,794,360
Granted (in shares)	1,150,600
Forfeited (in shares)	(110,900)
Outstanding at end of year (in shares)	2,834,060
Vested and exercisable at end of year (in shares)	736,561
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 7.83
Granted (in dollars per share)	8.77
Forfeited (in dollars per share)	8.92
Outstanding balance at end of year (in dollars per share)	8.17
Vested and exercisable balance at end of year (in dollars per share)	$ 8.09
Aggregate intrinsic value
Outstanding at end of year (in dollars)	$ 6,547
Vested and exercisable at end of year (in dollars)	$ 1,760
Stock Option Plan 2015 | Options
Share-Based Payments
Vesting period	4 years
Stock Option Plan 2015 | Options | First year
Share-Based Payments
Vesting period	1 year
Percentage that vests during the period	25.00%
Stock Option Plan 2015 | Options | Second, third and fourth years
Share-Based Payments
Vesting period	4 years
Percentage that vests during the period	75.00%
Monthly vesting percentage	2.083%
Common Stock | Nabriva Therapeutics AG | Stock Option Plan 2015
Share-Based Payments
Number of awards that can be granted			346,235	177,499	95,000
Common Stock | Redomiciliation Transaction | Nabriva Therapeutics AG
Share-Based Payments
Ratio of exchange of ordinary shares		10.00%
Common Stock | Redomiciliation Transaction | Nabriva Therapeutics AG | Stock Option Plan 2015
Share-Based Payments
Ratio of exchange of ordinary shares		10.00%

Share-Based Payments - Stock 46

Share-Based Payments - Stock Option Plan 2015 Outstanding and Fair Value (Details) - Stock Option Plan 2015 $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2017USD ($)$ / sharesshares
Share-Based Payments
Share-based compensation expense (in dollars)	$ 1.1	$ 2.9
Weighted-average grant date fair value (in dollars per share) | $ / shares		$ 4.86
Granted (in shares) | shares		1,150,600
Fair Value Assumptions
Expected term of options (in years)		6 years 1 month 6 days
Other disclosures
Weighted-average remaining contractual life		8 years 9 months 18 days
Total unrecognized compensation related to non-vested options (in dollars)	$ 11.1	$ 11.1
Period of recognition of total unrecognized compensation related to options		1 year 6 months
Minimum
Fair Value Assumptions
Range of expected volatility (as a percent)		55.60%
Range of risk-free interest rate (as a percent)		1.90%
Maximum
Fair Value Assumptions
Range of expected volatility (as a percent)		58.10%
Range of risk-free interest rate (as a percent)		2.10%

Accrued Expenses and Other Li47

Accrued Expenses and Other Liabilities - Obligation (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Collective bargaining arrangement, Chemical industry
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Discount rate	1.30%
Annual salary increase rate	3.00%
Collective bargaining arrangement, Chemical industry | Minimum
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Retirement age for men (in years)	61 years 6 months
Retirement age for women (in years)	56 years 6 months
Collective bargaining arrangement, Chemical industry | Maximum
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Retirement age for men (in years)	65 years
Retirement age for women (in years)	65 years
Other non-current liabilities
Other non-current liabilities
Provision for jubilee payments obligation	$ 125,000	$ 107,000

Accrued Expenses and Other Li48

Accrued Expenses and Other Liabilities - Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Components of accrued expenses and other current liabilities:
Research and development related costs	$ 5,137	$ 8,716
Payroll and related costs	2,187	2,150
Accounting, tax and audit services	123	484
Other	985	1,976
Total other current liabilities	$ 8,432	$ 13,326

Commitments and Contingencies -

Commitments and Contingencies - Lease Arrangements (Details) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2007	Jun. 30, 2017	Dec. 31, 2016
Obligations payable under the lease agreement:
No later than 1 year		$ 1,029,000	$ 1,484,000
Later than 1 year and no later than 5 years		2,554,000	2,536,000
Later than 5 years		244,000	507,000
Total		3,827,000	4,527,000
Lease agreement for use of business and research premises at Vienna
Lease Arrangements
Term of the lease agreement, under which it can only be terminated under certain conditions	10 years
Monthly costs for facility management and security services		9,000	9,000
Lease agreement for use of business and research premises at Vienna | Premises and laboratory furniture
Lease Arrangements
Monthly rent		84,000	85,000
Lease agreement for use of office premises at King of Prussia, Suite 600
Lease Arrangements
Monthly rent		$ 40,000	$ 40,000

Commitments and Contingencies50

Commitments and Contingencies - Other contractual commitments and Contingencies (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Remaining payments to be made under other contractual agreements
No later than 1 year	$ 40,999,000	$ 51,685,000
Later than 1 year and no later than 5 years	2,007,000	6,241,000
Total	43,006,000	$ 57,926,000
Contingencies
Contingent liabilities	$ 0